Pulmonary Edema Therapeutics Market is Expected to be Flourished by Rapid Adoption of Novel Therapeutics
![]() |
Pulmonary Edema Therapeutics Market |
Pulmonary
edema refers to the buildup of fluid in the air sacs (alveoli) of the lungs. It
is caused due to increased vascular permeability or fluid backlog in the lungs.
Common causes include heart failure, kidney failure, severe asthma, infection,
pulmonary embolism, near drowning, etc. Symptoms include shortness of breath,
cough, chest tightness, fatigue, anxiety, blue lips or face. Pulmonary edema
therapeutics are used for fluid removal from the lungs and treating the
underlying condition. Diuretics, vasodilators, anti-inflammatory drugs, antibiotics,
oxygen therapy are some commonly used treatment options. Technological
advancement has led to the development of novel drug delivery modes like
inhaled pulmonary edema therapeutics that deliver drugs directly to the site of
action with improved bioavailability.
The global Pulmonary Edema Therapeutics Market is estimated to be valued at US$
12144.1 Mn in 2023 and is expected to exhibit a CAGR of 5.4% over the forecast
period 2023 to 2030, as highlighted in a new report published by Coherent
Market Insights.
Market Dynamics:
Rapid adoption of novel drug delivery systems and inhaled pulmonary edema
therapeutics are expected to drive the market growth over the forecast period.
Inhaled medications such as diuretics provide faster fluid removal from lungs
and improved therapeutic outcome in acute pulmonary edema. This increases
treatment effectiveness and compliance among patients. Growing burden of
associated disorders such as renal diseases and heart failure that increases
the risks of acute pulmonary edema also aids in market expansion. Though patent
expiries of major drugs may restrict market growth, development of advanced
formulations, combination therapies are opportunity areas for key players.
Segment Analysis
The pulmonary edema therapeutics market is segmented based on type, cause,
diagnosis, treatment, end-user and distribution channel. The cardiogenic
pulmonary edema segment dominates the market, accounting for over 60% share.
This is because most pulmonary edema cases are caused due to left ventricular
heart failure which results in high pressure inside the lungs causing leakage
of fluids from pulmonary capillaries into the lung tissue.
Pulmonary Edema Therapeutics Market PEST Analysis
Political: Governments across countries are increasingly funding research on
pulmonary disorders. Formation of associations to raise awareness about
pulmonary edema will positively impact the market.
Economic: Rising healthcare spending coupled with growing disposable incomes in
developing countries will drive market growth. However, high treatment costs
and lack of insurance in developing regions can hinder the market.
Social: Increasing prevalence of cardiovascular and respiratory diseases,
growing elderly population and changing lifestyle leading to obesity are major
social factors fueling the market.
Technological: Advancements in diagnosis technologies like high resolution CT
scans and ultrasounds have made diagnosis more accurate and less invasive.
Introduction of novel drug delivery systems for treatment is another
technological driver.
Key Takeaways
The Global
Pulmonary Edema Therapeutics Market Demand is expected to witness high
growth over the forecast period driven by factors such as rising incidence of
cardiovascular and respiratory disorders, increasing healthcare spending and
availability of advanced treatment options.
The
global Pulmonary Edema Therapeutics Market is estimated to be valued at US$
12144.1 Mn in 2023 and is expected to exhibit a CAGR of 5.4% over the forecast
period 2023 to 2030.
North America dominates the market due to high healthcare spending,
availability of advanced treatments and presence of major players. However,
Asia Pacific is poised to grow at the fastest pace led by expanding healthcare
infrastructure, growing medical tourism industry and rising disposable incomes
in the region.
Key players operating in the pulmonary edema therapeutics market are Crayola
LLC, Faber-Castell AG, Sargent Art, Reeves (Colart Group), Liquitex (Colart
Group), Sax Arts & Crafts, Prang (Dixon Ticonderoga Company), RASCHER GmbH,
Richeson Art Materials, Jovi S.L. These companies are focusing on new product
launches, collaborations and geographic expansion to strengthen their market
position.
For more details on the report, Read- https://www.pressreleasebulletin.com/pulmonary-edema-therapeutics-market-growth/
Comments
Post a Comment